Press release
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.\n\n“I’m extraordinarily pleased with our business performance this past quarter,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “The FDA’s approval of our Tyvaso DPI medicine and recent major medical journal publications demonstrate our continuing product development success. I’m especially excited about our ongoing registration trials, such as PERFECT for assessing Tyvaso’s usefulness in COPD-associated pulmonary hypertension, ADVANCE OUTCOMES for studying whether once-daily ralinepag can reduce morbidity and mortality in pulmonary arterial hypertension, and TETON which is intended to demonstrate the disease-modifying potential of Tyvaso in idiopathic pulmonary fibrosis. Also very significant is our ARTISAN study, which will confirm whether Remodulin can be a short-term bridge to Orenitram when dosed rapidly to reduce right heart afterload and improve right ventricular structure and function.”\n\n“We ended the second quarter with a record number of patients on our treprostinil therapies, including the addition of approximately 500 Tyvaso patients this quarter,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “The recent approval and launch of Tyvaso DPI, coupled with the Medicare coverage decision for Tyvaso in PH-ILD, will provide additional momentum toward reaching our goal of 6,000 patients on Tyvaso by the end of the year.”\n\nSECOND QUARTER 2022 FINANCIAL RESULTS\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended\nJune 30,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nRevenues\n\n\n\n$\n\n\n\n466.9\n\n\n\n \n\n\n\n$\n\n\n\n446.5\n\n\n\n \n\n\n\n$\n\n\n\n20.4\n\n\n\n \n\n\n\n \n\n\n\n5\n\n\n\n%\n\n\n\n\n\nNet income\n\n\n\n$\n\n\n\n116.0\n\n\n\...